Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
NCT00077987 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84
Last updated 2007-01-11
Summary
Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.
Conditions
- Colorectal Neoplasms
Interventions
- DRUG
-
SU011248
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-12-31
- Completion
- 2005-04-30
More Related Trials
-
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
NCT00118105 ·Status: WITHDRAWN ·Phase: PHASE2
-
Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
NCT02497157 ·Status: COMPLETED ·Phase: PHASE2
-
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
NCT00851045 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer
NCT00378066 ·Status: COMPLETED ·Phase: PHASE2
-
S9923 R115777 in Treating Patients With Advanced Colorectal Cancer
NCT00005833 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
NCT00778102 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849 ·Status: RECRUITING ·Phase: PHASE3
-
S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
NCT00974389 ·Status: UNKNOWN ·Phase: PHASE2
-
Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer
NCT07051785 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT00826540 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
NCT00114946 ·Status: TERMINATED ·Phase: PHASE4
-
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
NCT02305758 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
NCT03414983 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
NCT00337389 ·Status: UNKNOWN ·Phase: PHASE3
-
Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line
NCT05372198 ·Status: UNKNOWN ·Phase: PHASE2
-
Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer
NCT01022541 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer
NCT00220116 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800 ·Status: RECRUITING ·Phase: PHASE3
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT05806931 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
NCT00159432 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
NCT03303495 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
NCT00116506 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
NCT05064059 ·Status: COMPLETED ·Phase: PHASE3
-
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
NCT01418222 ·Status: COMPLETED ·Phase: PHASE2